Sara Guariglia,  —

Articles by

Roche Acquires TMEM16A Portfolio for CF Treatment

Roche has acquired Enterprise Therapeutics’s TMEM16A potentiator portfolio, which includes ETD002, a therapeutic candidate being evaluated in Phase 1 clinical trials for the treatment of cystic fibrosis (CF). The TMEM16A portfolio is focused on treatments for CF and other severe respiratory disorders characterized by excessive mucus…

Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.